CN109512838B

CN109512838B - Rabbit skin extract and preparation method and application thereof

Info

Publication number: CN109512838B
Application number: CN201710829641.1A
Authority: CN
Inventors: 冯世庆; 孔晓红; 姚雪; 冯翊坤; 李波; 孙超
Original assignee: Tianjin Xiaoxi Biomedical Technology Co ltd
Current assignee: Tianjin Xiaoxi Biomedical Technology Co ltd
Priority date: 2017-09-15
Filing date: 2017-09-15
Publication date: 2022-05-10
Anticipated expiration: 2037-09-15
Also published as: CN109512838A

Abstract

The application relates to a rabbit skin extract and a preparation method and application thereof. In particular, the present application provides a method for preparing a rabbit skin extract, and a rabbit skin extract prepared by the method. In addition, the application also provides a composition containing the rabbit fur extract and application of the rabbit fur extract.

Description

Rabbit skin extract and preparation method and application thereof

Technical Field

The present application relates to the fields of immunology and biomedicine. In particular, the application relates to a rabbit skin extract, and a preparation method and application thereof. More specifically, the present application provides a method for preparing a rabbit fur extract, and a rabbit fur extract prepared by the method. In addition, the application also provides a composition containing the rabbit fur extract and application of the rabbit fur extract.

Background

The inflammatory skin extract of rabbit inoculated with vaccinia virus contains non-protein active substances extracted and separated from inflammatory skin tissue of rabbit infected with vaccinia virus. Such extracts are liquid in the extracted state, but may also be made solid by drying. Such extracts have been reported in the literature to be useful in the treatment of lumbago, cervical-shoulder-wrist syndrome, symptomatic neuralgia, pruritus associated with skin diseases (eczema, dermatitis, urticaria), allergic rhinitis, psychrotogenic-abnormal-sensation pain of the sequelae of subacute neuromyelitis (SMON) (see, for example, CN 103110663A). Based on the biological activity of such extracts, preparations containing extracts of vaccinia virus-inoculated rabbit inflamed skin (neuroleptine/NEUR 0TR0PIN, also referred to herein simply as "NTP" or "NTP preparation") have been developed.

However, the preparation of such rabbit skin extracts using conventional processes is time consuming and laborious. For example, chinese patent applications CN1493302A, CN103110663A, CN105163746A, CN106109498A and CN106573020A all disclose methods for extracting rabbit skin extract; however, in these extraction methods, the time consumption of only the preliminary extraction step reaches 6 to 11 days, which is very time-consuming. Meanwhile, in the conventional extraction method of rabbit skin extract, organic solvent (such as phenol) is usually used, which causes potential risks in terms of safety and reliability of the extract, environmental safety, and the like.

Therefore, there is a need in the art to develop a new method for preparing rabbit fur extract to reduce the time consumption of the extraction step and improve the extraction efficiency. Furthermore, there is a need in the art to develop new methods of preparing rabbit fur extracts to reduce or avoid the use of organic solvents (e.g., phenol) and thereby improve the safety and reliability of the obtained rabbit fur extracts.

Disclosure of Invention

After extensive research, the inventors of the present application developed a new method for preparing rabbit fur extract. Compared with the conventional method for preparing the rabbit skin extract, the preliminary extraction step (i.e., step (B)) of the preparation method of the present invention requires only 12-30 hours, and the time consumption of the step can be reduced by more than 75%, thereby greatly improving the extraction efficiency. Meanwhile, the preparation method of the invention can not use any organic solvent (such as phenol), thereby ensuring that the quality of the obtained rabbit fur extract is more stable, safe and reliable (for example, the obtained rabbit fur extract does not contain any organic solvent). In addition, the inventors of the present application have also unexpectedly found that the rabbit fur extract prepared by the method of the present invention contains higher content of gamma-aminobutyric acid (GABA), citrulline, and/or carnosine, and thus has more excellent technical effects (e.g., has higher GABA activity). The present application is therefore directed to at least the following aspects.

In one aspect, the present invention provides a method for preparing a rabbit skin extract, the method comprising the steps of:

(A) providing pox-raised skin from a vaccinia virus-inoculated rabbit;

(B) mixing the skin with water and stirring for 2-10 hours to obtain a mixture; subsequently, the pH of the mixture is adjusted to 9.5-10.5 and stirring is continued for 10-20 hours;

(C) subjecting the product of step (B) to solid-liquid separation (e.g. suction filtration, filtration and/or centrifugation) to obtain a first extract; and

(D) preparing the rabbit fur extract using the first extraction solution.

In certain preferred embodiments, the vaccinia virus (vaccinia virus) may be any strain of vaccinia virus, including, but not limited to, the Lister strain of vaccinia virus (Lis ter), the Dalian (Dairen) strain of vaccinia virus, the Pond of vaccinia virus (Ikeda) strain, the EM-63 strain of vaccinia virus, the New York City public health Board of health th strain of vaccinia virus, the Ankara (Ankara) strain of vaccinia virus, the Copenhagen (Copenhagen) strain, the Tiantan (Tian Tan) strain of vaccinia virus, the WR strain of vaccinia virus, buffalo pox virus, and the like.

In certain preferred embodiments, the rabbit may be any rabbit belonging to lagomorphic order, including, but not limited to, a rabbit (i.e., a rabbit to which a rabbit is acclimatized), a hare (e.g., a japanese hare), a mouse rabbit, a snow rabbit, and the like. In certain preferred embodiments, the rabbit is a rabbit. In certain preferred embodiments, the rabbit may be any breed (bred) rabbit, including, but not limited to, japanese white breed rabbits and new zealand white breed (new zealand white) rabbits.

Vaccinia virus-inoculated rabbit pox-raised skin can be obtained by various methods. In certain preferred embodiments, vaccinia-primed skin of rabbits vaccinated with vaccinia virus is obtained by vaccinating rabbits and then harvesting the pox-primed inflammatory skin. In certain preferred embodiments, vaccinia virus-inoculated rabbit pox-raised skin is commercially available.

In certain preferred embodiments, the skin is pretreated prior to performing step (B). In certain preferred embodiments, the pretreatment comprises freezing, thawing, washing, disinfecting, sonicating, fragmenting, or any combination thereof. In certain preferred embodiments, the skin is washed and/or disinfected prior to performing step (B). In certain preferred embodiments, the skin is subjected to a disruption treatment prior to step (B). In certain preferred embodiments, the skin is subjected to a cleaning, disinfecting and disrupting treatment prior to step (B). In certain preferred embodiments, the skin is subjected to freezing, thawing, washing, disinfecting and disrupting treatments prior to step (B). In certain preferred embodiments, the disruption treatment comprises (a) grinding in liquid nitrogen, (b) pulverizing in a pulverizer, or (c) a combination of (a) and (b). In certain preferred embodiments, the skin is subjected to a disruption treatment prior to step (B), thereby disrupting the skin into particulate matter. Preferably, the particle size of the particulate material is 50-500. mu.m, such as 50-75. mu.m, 75-100. mu.m, 100-150. mu.m, 150-200. mu.m, 200-500. mu.m, or 75-200. mu.m. In certain preferred embodiments, the skin is subjected to a disruption treatment prior to step (B), thereby disrupting the skin into particles, and the particles are subsequently placed at 30-40 ℃ (e.g., 30-32 ℃, 32-35 ℃, 35-37 ℃, or 37-40 ℃) for 4-16 hours (e.g., 4-8 hours, 8-12 hours, or 12-16 hours). Without being bound by any theory, it is generally believed that the skin disruption treatment is advantageous because it can facilitate the extraction of active substances in the skin tissue.

In certain preferred embodiments, in step (B), the weight to volume ratio of skin to water (g/ml) is 1 (1-5), e.g., 1 (1-1.5), 1 (1.5-2), 1 (2-2.5), 1 (2.5-3), 1 (3-4) or 1 (4-5). In certain preferred embodiments, in step (B), the weight to volume ratio of skin to water is 1: 2.5. In certain preferred embodiments, in step (B), the skin is mixed with water at room temperature (e.g., 15-35 ℃, 15-20 ℃, 20-25 ℃, 25-30 ℃ or 30-35 ℃) and stirred for 2-10 hours (e.g., 2-4 hours, 4-6 hours, 6-8 hours or 8-10 hours) to obtain a mixture.

In certain preferred embodiments, in step (B), the pH of the mixture is adjusted to 9.5-10.5, for example to pH10, using a base. In certain preferred embodiments, the base is an inorganic base, such as NaOH or KOH. In certain preferred embodiments, in step (B), the pH of the mixture is adjusted to 9.5 to 10.5 and stirring is continued at elevated temperature (e.g., 40-50 ℃, 40-42 ℃, 42-45 ℃, 45-48 ℃ or 48-50 ℃) for 10-20 hours (e.g., 12-14 hours, 14-16 hours, 16-18 hours or 18-20 hours).

In the process of the present invention, in step (B), by using a two-stage extraction scheme, i.e., extraction with water followed by extraction with an alkaline solution (particularly an alkaline solution), the extraction time consumed by this step is greatly reduced (i.e., it can be reduced to 12-30 hours). Compared to the previously reported extraction method, such as the extraction method disclosed in CN103110663A, the primary extraction step of which takes 6-11 days, the time consumption of the primary extraction step (i.e., step (B)) of the method of the present invention can be reduced by more than 75%, thereby greatly improving the extraction efficiency.

In certain preferred embodiments, in step (C), the product of step (B) is subjected to solid-liquid separation by filtration or suction filtration; preferably, the product of step (B) is filtered or suction filtered at a filter pore size of 50-500 μm (e.g., 50-75 μm, 75-100 μm, 100-150 μm, 150-200 μm, 200-500 μm, or 75-200 μm).

In certain preferred embodiments, step (D) of the process of the invention comprises the steps of:

(D1) adjusting the pH of the first extract to 4.0-5.0, performing heat treatment, and subsequently performing solid-liquid separation (e.g., performing suction filtration, filtration and/or centrifugation) to obtain a second extract;

(D2) adjusting the pH of the second extract to 9.0-10.0, heating, and performing solid-liquid separation (such as suction filtration, filtration and/or centrifugation) to obtain a third extract;

(D3) adjusting the pH of the third extractive solution to 3.5-5.5, and contacting with adsorbent to make active substances in the third extractive solution adsorbed on the adsorbent;

(D4) performing solid-liquid separation (for example, suction filtration, filtration and/or centrifugation) on the product of the step (D3), and collecting the adsorbent; and

(D5) extracting the active substance adsorbed on the adsorbent with an extraction solvent having a pH of 9.0-11.0 to obtain a fourth extract, i.e. rabbit skin extract.

In certain preferred embodiments, in step (D1), the pH of the first extract is adjusted to 4.0-5.0, for example to pH4.5, using an acid. In certain preferred embodiments, the acid is a mineral acid, such as HCl. In certain preferred embodiments, in step (D1), the pH of the first extract is adjusted to 4.0-5.0 and heated to 85-105 deg.C (e.g., 85-90 deg.C, 90-95 deg.C, 95-100 deg.C, or 100-105 deg.C). In certain preferred embodiments, in step (D1), the heat treatment is carried out for 0.5 to 1.5 hours, such as 0.5 to 1 hour or 1 to 1.5 hours. Without being bound by any theory, it is generally believed that heat treatment under acidic conditions may help remove some of the contaminating proteins in the extract. In certain preferred embodiments, in step (D1), the second extract is obtained by solid-liquid separation by centrifugation followed by filtration or suction filtration.

In certain preferred embodiments, in step (D2), the pH of the second extract is adjusted to 9.0-10.0, for example to pH9.5, using a base. In certain preferred embodiments, the base is an inorganic base, such as NaOH or KOH. In certain preferred embodiments, in step (D2), the pH of the second extract is adjusted to 9.0-10.0 and heated to 85-105 deg.C (e.g., 85-90 deg.C, 90-95 deg.C, 95-100 deg.C, or 100-105 deg.C). In certain preferred embodiments, in step (D2), the heat treatment is carried out for 0.25 to 1.5 hours, such as 0.25 to 0.5 hours, 0.5 to 1 hour, or 1 to 1.5 hours. In certain preferred embodiments, in step (D2), after the second extract liquid is subjected to the heat treatment, it is stirred for 10 to 20 hours (e.g., 10 to 12 hours, 12 to 14 hours, 14 to 16 hours, 16 to 18 hours, or 18 to 20 hours), and then subjected to solid-liquid separation, thereby obtaining a third extract liquid. Without being bound by any theory, it is generally believed that the heat treatment under alkaline conditions and the subsequent agitation treatment may help to remove a portion of the contaminating proteins in the extraction solution. In certain preferred embodiments, in step (D2), the third extract is obtained by solid-liquid separation by filtration or suction filtration (for example, using a filter membrane having a pore size of 0.22 to 0.65 μm (for example, 0.45 μm)).

In certain preferred embodiments, in step (D3), the pH of the third extract is adjusted to 3.5-5.5, e.g., 3.5-4.0, 4.0-4.5, 4.5-5.0, or 5.0-5.5, using an acid. In certain preferred embodiments, the acid is a mineral acid, such as HCl. In certain preferred embodiments, in step (D3), the adsorbent is selected from the group consisting of activated carbon, kaolin, and any combination thereof. In certain preferred embodiments, the weight ratio (g/g) of the adsorbent used in step (D3) to the skin used in step (B) is 1 (10-50), e.g., 1 (10-15), 1 (15-20), 1 (20-25), 1 (25-30), 1 (30-40), or 1 (40-50). In certain preferred embodiments, in step (D3), the pH of the third extract may be adjusted to 3.5 to 5.5 prior to, simultaneously with, or after contacting with the adsorbent. In certain preferred embodiments, in step (D3), the pH of the third extract is adjusted to 3.5-5.5 and contacted (e.g., mixed) with an adsorbent, followed by stirring at room temperature (e.g., 15-35 ℃, 15-20 ℃, 20-25 ℃, 25-30 ℃, or 30-35 ℃) for 1-4 hours, e.g., 1-2 hours, 2-3 hours, or 3-4 hours. In certain preferred embodiments, in step (D3), the adsorbent is packed in an adsorption column and then contacted with the pH-adjusted third extract to adsorb the active substance in the third extract. Without being bound by any theory, it is generally believed that the use of suitable agitation and/or packed columns may facilitate adsorption of the active substance in the third extract onto the adsorbent.

In certain preferred embodiments, in step (D4), the product of step (D3) is subjected to solid-liquid separation by filtration or suction filtration (e.g., using filter paper), thereby obtaining an adsorbent having an active substance adsorbed thereon.

In certain preferred embodiments, step (D5) comprises contacting (e.g., mixing) the adsorbent with an extraction solvent having a pH of 9.0 to 11.0, followed by solid-liquid separation (e.g., suction filtration, and/or centrifugation) to obtain a fourth extract. In certain preferred embodiments, in step (D5), the extraction solvent is a basic solution (e.g., a basic aqueous solution, a methanol solution, an ethanol solution, an isopropanol solution, or any combination thereof; preferably, a solution of a base). In certain preferred embodiments, in step (D5), the active material adsorbed on the adsorbent is extracted using an alkaline solution (e.g., an alkaline aqueous solution, a methanol solution, an ethanol solution, an isopropanol solution, or any combination thereof; preferably, a solution of an alkali) having a pH of 9.0 to 11.0 (e.g., a pH of 9.0 to 9.5, 9.5 to 10.0, 10.0 to 10.5, or 10.5 to 11.0). In certain preferred embodiments, the solution of the base is an aqueous solution of an inorganic base, such as NaOH or KOH. In certain preferred embodiments, the weight to volume ratio (g/ml) of the adsorbent used in step (D3) to the extraction solvent used in step (D5) is 1 (10-100), e.g., 1 (10-20), 1 (20-30), 1 (30-40), 1 (40-50), 1 (50-60), 1 (60-70), 1 (70-80), 1 (80-90), or 1 (90-100). In certain preferred embodiments, in step (D5), the active material adsorbed on the adsorbent is extracted with the extraction solvent under heating and/or stirring. Without being bound by any theory, it is generally believed that suitable agitation and/or heat treatment may facilitate elution of the active substance from the adsorbent. In certain preferred embodiments, in step (D5), the active material adsorbed on the adsorbent is extracted with the extraction solvent at a temperature of 40 to 50 ℃ (e.g., 40 to 42 ℃, 42 to 45 ℃, 45 to 48 ℃, or 48 to 50 ℃) and under stirring conditions (e.g., stirring for 1 to 4 hours, e.g., 1 to 2 hours, 2 to 3 hours, or 3 to 4 hours). In certain preferred embodiments, in step (D5), the active substance adsorbed on the adsorbent is extracted one or more times, for example at least 2 times, with the extraction solvent; the extracts obtained from each extraction are then combined to obtain a fourth extract. It will be readily appreciated that when the active material adsorbed on the adsorbent is extracted with an extraction solvent, the extraction solvent used for each extraction may be the same or different. For example, in certain preferred embodiments, in step (D5), the first extraction is performed with an extraction solvent having a pH of 9.0 to 10.0, and then the second extraction is performed with an extraction solvent having a pH of 10.0 to 11.0, and then the extracts obtained from the two extractions are combined to obtain a fourth extract.

In certain preferred embodiments, the method further comprises, after step (D), one or more steps selected from the group consisting of:

(E1) performing ultrafiltration on the fourth extract;

(E2) heating the fourth extract;

(E3) adjusting the pH of the fourth extract to 6.5-7.5;

(E4) diluting or concentrating the fourth extract;

(E5) sterilizing the fourth extract; and

(E6) and carrying out freeze-drying treatment on the fourth extracting solution.

In certain preferred embodiments, ultrafiltration is carried out with a molecular weight cut-off of 5-40kD, e.g., 5-10kD, 10-15kD, 15-20kD, 20-30kD or 30-40kD, in step (E1). In certain preferred embodiments, in step (E2), the fourth extract is heated to 60-100 ℃, e.g., 60-70 ℃, 70-80 ℃, 80-90 ℃ or 90-100 ℃, and optionally allowed to stand for 10-18 hours, e.g., 10-12 hours, 12-14 hours, 14-16 hours or 16-18 hours. In certain preferred embodiments, in step (E3), the pH of the fourth extract is adjusted to 6.5-7.5, e.g., 6.5-7.0 or 7.0-7.5, using an acid. In certain preferred embodiments, the acid is a mineral acid, such as HCl. In certain preferred embodiments, in step (E4), the fourth extract is diluted with water for injection, physiological saline or physiological buffer. In certain preferred embodiments, in step (E4), the fourth extract is concentrated to a desired concentration. In certain preferred embodiments, in step (E5), the fourth extract is sterilized using autoclaving, ultra high temperature sterilization (UHT), pasteurization, filter sterilization, or any combination thereof.

In certain preferred embodiments, the method further comprises 1, 2, 3, 4, 5, or 6 of steps (E1) - (E6) after step (D). In certain preferred embodiments, the method further comprises steps (E1) - (E5) after step (D4). In the method of the present invention, after step (D), 1, 2, 3, 4, 5 or 6 of steps (E1) - (E6) may be performed in any desired order according to actual needs.

In certain preferred embodiments, in step (B) of the process of the present invention, no phenol is used. In certain preferred embodiments, no organic solvent is used in step (B) of the process of the present invention. In certain preferred embodiments, the process according to the present invention does not use phenol. In certain preferred embodiments, the process according to the invention does not use an organic solvent. It is believed that the use of phenol can achieve two technical effects: on one hand, phenol can be used as a bactericide to play a role in sterilization and disinfection; on the other hand, phenol acts as an organic solvent, which facilitates the extraction of the active substance. However, in some cases, it is desirable to avoid the use of any organic solvent (e.g. phenol) as much as possible during the extraction of the active substance or the preparation of the drug, in order to avoid residues of such organic solvent (e.g. phenol) in the final product, which could affect subsequent applications (e.g. clinical applications). In certain preferred embodiments of the present invention, the process of the present invention (especially step (B)) does not require the use of any organic solvent (e.g. phenol), and thus the rabbit skin extract obtained does not contain any organic solvent. The process of the invention and the rabbit skin extract thus obtained are therefore particularly advantageous.

In another aspect, the present invention provides a rabbit skin extract, which is prepared by the above method. As described above, the preferred preparation method of the present invention may not use any organic solvent. Accordingly, the rabbit skin extracts prepared by such methods will be completely free of any organic solvents, which is particularly advantageous in some cases.

Further, the rabbit skin extract is an extract derived from inflamed skin tissue of a rabbit which has been pox-infected with vaccinia virus, and contains a very large variety of substances. In other words, the rabbit skin extract and the preparation prepared using the rabbit skin extract do not have a specific 1 or more substances as active ingredients, and the activity/potency thereof cannot be determined simply by measuring the content of one or more active ingredients. In order to objectively evaluate the activity/potency of rabbit skin extracts, it has been proposed to quantify the active ingredients of rabbit skin extracts by measuring the biological activity (potency). Briefly, SART-stressed (repeated cold load) animals, which are chronically stressed animals with lower pain thresholds than normal animals, were used according to the method described in "journal of medicine" (Vol.72, No. 5, p. 573-584, 1976)) The analgesic activity of the rabbit skin extract was measured by an analgesic test by a transpedicular (Randal l-Sel itto) method. In the inflammatory foot compression method, a pressure stimulus is applied to the tail of a mouse, and the analgesic effect is measured using the compression weight until the mouse shows an escape response as an index. The analgesic coefficient is a value obtained by dividing the weight under pressure measured after administration of the drug by the weight under pressure measured before administration of the drug. The activity of the rabbit skin extract was regarded as positive in analgesic effect when it showed an analgesic coefficient of a predetermined value or more, and the ratio of the number of animals judged to be positive was determined as analgesic effective rate (%). Subsequently, ED was calculated from the results measured for the standards diluted to various concentrations₅₀The value is obtained. Thus, the unit for evaluating the biological activity (potency) of rabbit skin extracts is defined as follows: will ED₅₀The activity exhibited by the rabbit skin extract lmg at a value of 100mg/kg (mouse body weight) administered is defined as 1 Neuropin unit (i.e., 1 NU). In the present application, when describing the amount (titer) of an active ingredient of a rabbit fur extract or a preparation, a unit (sometimes also referred to simply as "unit", U) of NU is used for expression. In the art, NU units have been used to describe the amount of active ingredient (potency) of rabbit skin extracts or related preparations. For example, currently marketed NTP injections contain 1.2NU units/ml of active ingredient, and NTP tablets contain 4NU units/tablet of active ingredient. In this application, "Neurotropin unit", "NU" and "U" have the same meaning and are used interchangeably.

The present inventors have also found that the rabbit skin extract of the present invention contains higher amounts of gamma-aminobutyric acid (GABA), citrulline, and/or carnosine per NU unit than rabbit skin extracts prepared by conventional methods (e.g. the method disclosed in CN 103110663A).

Gamma-aminobutyric acid (GABA) is a naturally occurring non-protein amino acid. Studies have shown that GABA is an important inhibitory neurotransmitter in the mammalian central nervous system, plays an important role in the cerebral cortex, hippocampus, thalamus, basal ganglia and cerebellum of the human body, and has a regulatory effect on various functions of the body. For example, GABA can reduce neuronal activity, prevent neuronal cell overheating (overheating), and achieve anxiolytic effects. In addition, GABA can act on the vasomotor center of the spinal cord, effectively promote the expansion of blood vessels and realize the effect of reducing blood pressure. Citrulline is an alpha amino acid. Studies have shown that citrulline can relax blood vessels, and can be used to enhance male sexual function, as well as to treat sexual dysfunction. In addition, citrulline can maintain healthy lung function, improve mental clarity and help improve the ability of brain nerve cells to store and recall messages. Carnosine, beta-alanyl-L-histidine, is a dipeptide consisting of two amino acids, beta-alanine and L-histidine. Research shows that the carnosine has strong oxidation resistance, and animal experimental data show that the carnosine can delay the growth of cancer cells, prevent oxidation pressure caused by alcohol, reduce chronic liver injury caused by alcohol, has a neuroprotective effect, and can prevent permanent cerebral ischemia injury. Therefore, rabbit skin extracts of the invention containing higher levels of GABA, citrulline, and/or carnosine are particularly advantageous. The rabbit fur extract prepared by the method is unique and has better application prospect.

Thus, in another aspect, the invention provides a rabbit skin extract which does not contain any organic solvent (e.g. phenol) and which contains at least 0.8ng of γ -aminobutyric acid per NU unit of rabbit skin extract, e.g. at least 1ng, at least 2ng, at least 5ng, at least 10ng, at least 20ng, at least 50ng, at least 70ng, at least 100ng, at least 120ng, or at least 150ng of γ -aminobutyric acid. In certain preferred embodiments, the rabbit skin extract comprises 0.8-150ng of gamma-aminobutyric acid per NU unit, such as 0.8-1ng, 1-2ng, 2-5ng, 5-10ng, 10-20ng, 20-50ng, 50-70ng, 70-100ng, 100-120ng, or 120-150ng of gamma-aminobutyric acid.

In certain preferred embodiments, at least 4ng of carnosine is present per NU unit of rabbit skin extract, e.g., at least 5ng, at least 7ng, at least 10ng, at least 12ng, at least 15ng, at least 20ng, at least 22ng, at least 25ng, or at least 30ng of carnosine is present. In certain preferred embodiments, the rabbit skin extract contains 4-30ng carnosine per NU unit, e.g., 4-5ng, 5-7ng, 7-10ng, 10-12ng, 12-15ng, 15-20ng, 20-22ng, 22-25ng, or 25-30ng carnosine.

In certain preferred embodiments, at least 60ng citrulline, e.g., at least 80ng, at least 100ng, at least 120ng, at least 150ng, at least 170ng, or at least 200ng citrulline, is present in rabbit skin extract per NU unit. In certain preferred embodiments, 60-200ng citrulline is present in rabbit skin extract per NU unit, e.g., 60-80ng, 80-100ng, 100-120ng, 120-150ng, 150-170ng, or 170-200ng citrulline.

In certain preferred embodiments, the rabbit skin extract is prepared by the methods of the invention.

In another aspect, the present invention also provides a composition comprising the rabbit fur extract as described above (in particular, the rabbit fur extract obtained by the process of the present invention).

In the present application, the inventors have found, after extensive studies, that a rabbit skin extract prepared using the pox-raised skin of a rabbit inoculated with vaccinia virus can promote the proliferation of various cells such as oligodendrocytes, mesenchymal stem cells (e.g., bone marrow mesenchymal stem cells) and neural stem cells; in addition, the rabbit fur extract prepared by the method has particularly remarkable and good effect of promoting cell proliferation. Therefore, the rabbit fur extract of the present invention can be added to a cell culture medium for promoting cell proliferation. Thus, in certain preferred embodiments, the composition is a cell culture medium comprising rabbit skin extract obtained by the process of the invention. In certain preferred embodiments, the cell culture medium is DMEM medium, F12 medium or DMEM/F12 medium supplemented with rabbit skin extract according to the invention. DMEM medium, F12 medium or DMEM/F12 medium can be prepared by conventional methods or can be obtained commercially. In certain preferred embodiments, the cell culture medium further comprises additional agents, such as serum (e.g., fetal bovine serum), cytokines, B27 cell culture additives (B27), or any combination thereof. In certain preferred embodiments, the cytokines include, but are not limited to, Epidermal Growth Factor (EGF), Leukemia Inhibitory Factor (LIF), fibroblast growth factor (FGF; including, but not limited to, aFGF and bFGF), or any combination thereof.

In addition, it has been previously reported that rabbit skin extracts prepared using pox-raised skin of rabbits inoculated with vaccinia virus can be used for the treatment of various diseases or disorders. Such diseases or disorders include, but are not limited to, lumbago, neck-shoulder-wrist syndrome, symptomatic neuralgia, pruritus accompanied by skin diseases (e.g., eczema, dermatitis, urticaria), allergic rhinitis, psychroaesthetic-abnormal-pain of subacute neuromyelitis optica sequela, postherpetic neuralgia, scapulohumeral periarthritis, osteoarthritis, etc. (see, for example, CN 103110663A). In addition, it has been found that the rabbit fur extract can be used for treating central nervous system diseases such as Traumatic Brain Injury (TBI) and Spinal Cord Injury (SCI), for promoting motor function recovery after spinal cord injury, or for inhibiting glial scarring, particularly after spinal cord injury. Therefore, the rabbit fur extract of the present invention can be used for preparing a medicament or a pharmaceutical composition for treating the disease or disorder. Thus, in certain preferred embodiments, the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier or excipient. In certain preferred embodiments, the pharmaceutical composition is an injection containing rabbit skin extract according to the present invention. In certain preferred embodiments, the pharmaceutical composition is a tablet comprising rabbit skin extract according to the invention. In certain preferred embodiments, the pharmaceutical composition is in a pharmaceutical dosage form suitable for systemic intravenous administration, such as an injection or a lyophilized powder.

As discussed above, the rabbit fur extract of the present invention can promote the proliferation of various cells. Thus, in another aspect, there is also provided the use of a rabbit skin extract of the invention for culturing cells in vitro or for promoting cell proliferation in vitro. In certain preferred embodiments, the cell is selected from the group consisting of an oligodendrocyte, a mesenchymal stem cell (e.g., a bone marrow mesenchymal stem cell), and a neural stem cell. In certain preferred embodiments, the use is for non-diagnostic or therapeutic purposes.

In another aspect, there is also provided the use of the rabbit skin extract of the invention for the preparation of a composition for culturing cells or for promoting cell proliferation. In certain preferred embodiments, the cell is selected from the group consisting of an oligodendrocyte, a mesenchymal stem cell (e.g., a bone marrow mesenchymal stem cell), and a neural stem cell. In certain preferred embodiments, the composition is a cell culture medium comprising a rabbit skin extract of the invention. In certain preferred embodiments, the composition is DMEM medium, F12 medium, or DMEM/F12 medium comprising the rabbit skin extract of the invention. In certain preferred embodiments, the cell culture medium further comprises additional agents, such as serum (e.g., fetal bovine serum), cytokines, B27 cell culture additives (B27), or any combination thereof. In certain preferred embodiments, the cytokines include, but are not limited to, Epidermal Growth Factor (EGF), Leukemia Inhibitory Factor (LIF), fibroblast growth factor (FGF; including, but not limited to, aFGF and bFGF), or any combination thereof.

In another aspect, the present invention provides a method for culturing cells in vitro or promoting cell proliferation in vitro, comprising the step of using the rabbit skin extract of the present invention. In certain preferred embodiments, the cell is selected from the group consisting of an oligodendrocyte, a mesenchymal stem cell (e.g., a bone marrow mesenchymal stem cell), and a neural stem cell. In certain preferred embodiments, the method comprises the step of culturing the cells in a cell culture medium comprising an extract of rabbit skin of the invention. In certain preferred embodiments, the cell culture medium is DMEM medium, F12 medium or DMEM/F12 medium comprising rabbit skin extract of the present invention. In certain preferred embodiments, the cell culture medium further comprises additional agents, such as serum (e.g., fetal bovine serum), cytokines, B27 cell culture additives (B27), or any combination thereof. In certain preferred embodiments, the cytokines include, but are not limited to, Epidermal Growth Factor (EGF), Leukemia Inhibitory Factor (LIF), fibroblast growth factor (FGF; including, but not limited to, aFGF and bFGF), or any combination thereof. In certain preferred embodiments, the methods are used for non-diagnostic or therapeutic purposes.

As discussed above, the rabbit fur extract of the present invention can be used for the treatment of various diseases or disorders. In another aspect, there is also provided a use of the rabbit skin extract of the present invention for the preparation of a medicament for treating lumbago, cervical-shoulder-wrist syndrome, symptomatic neuralgia, pruritus accompanied by skin diseases (e.g., eczema, dermatitis, urticaria), allergic rhinitis, psychroaesthetic-paresthesia-pain of subacute neuromyelitis syndrome sequelae, postherpetic neuralgia, scapulohumeral periarthritis, osteoarthritis, or central nervous system disease, for promoting motor function recovery after spinal cord injury, or for inhibiting glial scar formation. In certain preferred embodiments, the central nervous system disorder is selected from the group consisting of Traumatic Brain Injury (TBI) and Spinal Cord Injury (SCI). In certain preferred embodiments, the medicament is for promoting motor function recovery after spinal cord injury. In certain preferred embodiments, the medicament is for inhibiting glial scarring, particularly after spinal cord injury. In certain preferred embodiments, the spinal cord injury is a spinal cord injury caused by a fracture or dislocation of the spine (e.g., due to trauma such as an automobile accident or fall). In certain preferred embodiments, the glial scar formation is caused by glial cell proliferation following spinal cord injury. In certain preferred embodiments, the medicament further comprises a pharmaceutically acceptable carrier or excipient. In certain preferred embodiments, the medicament is in a pharmaceutical dosage form suitable for systemic intravenous administration, such as an injection or a lyophilized powder.

Advantageous effects of the invention

Compared with the prior art, the method for preparing the rabbit fur extract has the following beneficial effects: in the preliminary extraction step (i.e., step (B)) of the production method of the present invention, by using a two-stage extraction scheme, i.e., extraction with water followed by extraction with an alkaline solution (particularly, an alkaline solution), the extraction time consumed by the preliminary extraction step is greatly shortened (i.e., can be shortened to 12 to 30 hours). Compared with the previously reported extraction method, such as the extraction method disclosed in CN103110663A, the time consumption of the primary extraction step of which is as long as 6-11 days, the time consumption of the primary extraction step (i.e., step (B)) of the preparation method of the present invention can be reduced by more than 75%, thereby greatly improving the extraction efficiency.

Furthermore, in certain preferred cases, the preparation method of the present invention (especially step (B)) does not require any organic solvent (e.g. phenol) compared to the prior art, thereby ensuring more stable, safe and reliable quality of the obtained rabbit fur extract (e.g. the obtained rabbit fur extract does not contain any organic solvent). Therefore, the preparation method of the present invention and the rabbit fur extract obtained thereby are particularly advantageous.

In addition, the inventors of the present application have also found that the rabbit skin extract prepared by the method of the present invention contains gamma-aminobutyric acid (GABA), citrulline, and/or carnosine in higher amounts than the rabbit skin extract prepared by the conventional method (e.g., the method disclosed in CN103110663A), and thus has more excellent technical effects (e.g., has higher GABA activity). Therefore, the preparation method of the present invention and the rabbit fur extract obtained thereby are particularly advantageous. The rabbit fur extract has better effectiveness and safety and better application prospect.

In addition, the inventor of the present application also finds that the rabbit fur extract of the present invention can inhibit the formation of colloid scar after spinal cord injury, and significantly improve the BBB score of spinal cord injury animals. The rabbit fur extract has a remarkable promoting effect on motor function recovery after spinal cord injury.

Embodiments of the present invention will be described in detail below with reference to the drawings and examples, but those skilled in the art will understand that the following drawings and examples are only for illustrating the present invention and do not limit the scope of the present invention. Various objects and advantageous aspects of the present invention will become apparent to those skilled in the art from the accompanying drawings and the following detailed description of the preferred embodiments.

Drawings

FIG. 1 shows the results of HPLC detection (abscissa: time/min; ordinate: absorbance/mAU) of the rabbit skin extract prepared in example 1.

FIG. 2 shows the results of measurement of LV absorption spectrum of the rabbit skin extract obtained in example 1 (abscissa: wavelength/nm; ordinate: absorbance).

FIG. 3A shows the results of immunofluorescence assay (fluorescence micrograph) of cultured cells with anti-O4 antibody in example 2. The results showed that the cultured cells were positive for the anti-O4 antibody detection and were oligodendrocytes.

FIG. 3B shows the results of detection of cultured cells by DAPI staining (fluorescence micrograph) in example 2, in which stained nuclei are shown.

Fig. 3C is a merged image of fig. 3A and 3B. The results showed a 1:1 ratio of cells positive for anti-O4 antibody detection to cells stained with DAPI.

Fig. 4A-4C show the proliferation of each group of oligodendrocytes cultured in cell culture medium containing varying concentrations of rabbit skin extract at day 2 (fig. 4A), day 4 (fig. 4B), and day 6 (fig. 4C), respectively, after the start of the culture.

Fig. 5A-5B show proliferation of each set of mesenchymal stem cells cultured in cell culture medium containing rabbit skin extract at different concentrations on day 2 (fig. 5A) and day 4 (fig. 5B) after the start of culture, respectively.

FIG. 6A shows an optical micrograph of the cells cultured in example 4. The results showed that the cultured cells exhibited a shape of a cell sphere in suspension, which is transparent and has a strong stereoscopic impression and a radial burr on the periphery, and is unique to neural stem cells.

FIG. 6B shows the results of immunofluorescence assay (fluorescence micrograph) of cultured cells with anti-Nestin antibody in example 4. The results showed that the cultured cells were positive for the anti-nestin antibody detection and were neural stem cells.

FIG. 6C shows the results of detection of cultured cells by DAPI staining (fluorescence micrograph) in example 4, in which stained nuclei are shown.

Fig. 6D is a merged image of fig. 6B and 6C. The results showed that the ratio of cells positive for anti-Nestin antibody detection to cells stained with DAPI was 1: 1.

Fig. 7A to 7C show the proliferation of each group of neural stem cells cultured in the cell culture medium containing the rabbit skin extract at different concentrations on day 1 (fig. 7A), day 2 (fig. 7B), and day 3 (fig. 7C) after the start of the culture, respectively.

FIGS. 8A-8D show GABA currents in rat hippocampal neurons in the presence of GABA (10. mu.M), NTP injection + Bicuculline (10. mu.M), rabbit skin extract of the invention, or rabbit skin extract of the invention + Bicuculline (10. mu.M), respectively. FIGS. 8A-8B show the GABA current response of cell sample 1 (FIG. 8A) and cell sample 2 (FIG. 8B), respectively, to GABA, rabbit skin extract of the invention or rabbit skin extract of the invention + dicentrine. FIGS. 8C-8D show the GABA current response to GABA, NTP injection or NTP injection + bicuculline for cell sample 1 (FIG. 8C) and cell sample 2 (FIG. 8D), respectively.

Figure 9 shows motor function recovery (i.e., BBB score) after treatment of spinal cord injured rats with saline or a prescribed dose of rabbit skin extract.

FIG. 10 shows glial scarring (i.e., GFAP immunostaining) in spinal cord injured rats treated with saline or a prescribed dose of rabbit skin extract.

Detailed Description

The invention will now be described with reference to the following examples, which are intended to illustrate the invention, but not to limit it. The examples are given by way of illustration and are not intended to limit the scope of the invention as claimed.

The experimental procedures used in the following examples are conventional unless otherwise specified. Reagents and materials used in the following examples are commercially available products unless otherwise specified. Wherein, the sources of the used partial reagents and the kit are as follows:

DMEM/F12 cell culture medium was purchased from Gibco;

the cck-8 kit was purchased from bebo;

b27 was purchased from Invi trogen;

anti-O4 antibody, anti-Nestin antibody, and anti- β iii-tubulin antibody were purchased from Sigma-Aldrich;

anti-GFAP and anti-CNPase antibodies were purchased from Abcam; and

bFGF, EGF and LIF were all purchased from Peprotech.

Example 1 preparation of Rabbit skin extract

The skin of a rabbit (white breed New Zealand rabbit, body weight greater than 2.5kg) inoculated intradermally with the vaccinia virus Lister strain was collected and frozen in a freezer at-20 ℃ for use.

(A) Taking out frozen rabbit skin from a freezer at the temperature of-20 ℃, weighing 80g of the frozen rabbit skin, cutting the rabbit skin into small blocks of 2-3 cm, and placing the small blocks into liquid nitrogen while cutting. After all the rabbit skin is cut, the rabbit skin is put into a grinder and ground into particles (75-200 mu m). The pulverized rabbit skin is placed in a beaker, sealed with a preservative film, and left to thaw to room temperature (every half hour, measured once; in general, after liquid nitrogen treatment, the rabbit skin can reach room temperature in 2.5-3 hours). Subsequently, the rabbit skin was placed in a constant temperature incubator at 37. + -. 2 ℃ for 12 hours.

(B) The product obtained in (A) and 200ml of ultrapure water were placed in a beaker, and stirred at room temperature for 6 hours.

(C) The mixture obtained in (B) was transferred to a round-bottom flask and the pH was adjusted to 10.0. + -. 0.5 with 5mol/L NaOH while stirring, then extracted at 45 ℃ for 12-18 hours (overnight). Subsequently, the mixture in the round-bottomed flask was suction-filtered using an 80-mesh filter cloth using a suction-filtering apparatus connected to a vacuum pump, and the filtered liquid (first extract) was transferred to a new round-bottomed flask.

(D) The filtrate (first extract) obtained in (C) was adjusted to pH 4.5. + -. 0.5 with 5mol/LHCl while stirring, and heated at 95 ℃ for 60 minutes. After heating, the whole mixture was cooled to below 50 ℃, centrifuged at 10000rpm for 1 hour, filtered and the supernatant (second extract) was taken to a new round bottom flask.

(E) The supernatant (second extract) obtained in (D) was adjusted to pH 9.5. + -. 0.5 with 5mol/L NaOH while stirring, and heated at 95 ℃ for 30 minutes, then cooled and stirred overnight (12 to 18 hours). Then, the whole mixture was filtered with a suction filtration apparatus connected to a vacuum pump using a 0.45 μm filter, and the filtered liquid (third extract) was transferred to a new beaker.

(F) To the filtrate (third extract) obtained in (E), 4g of activated carbon was added, and pH was adjusted to 4.5. + -. 0.5 with 5mol/L HCl while stirring. After stirring at room temperature for 2 hours, the mixture was pressure-filtered through filter paper to obtain activated carbon, and the filtrate was discarded. Then, 200ml of ultrapure water was added to the active carbon having adsorbed the active ingredient, and the pH was adjusted to 10.0. + -. 0.5 with 5mol/L NaOH under stirring. After stirring at 45 ℃ for 2 hours, the mixture was pressure-filtered (filter paper, 0.22 μm filter), and the filtrate (fourth extract) was transferred to a blue-capped bottle. The fourth extract is the rabbit skin extract of the rabbit immunized by vaccinia virus.

(G) The filtrate (fourth extract) obtained in (F) was added to an ultrafilter, and subjected to ultrafiltration using a filter membrane having a molecular weight limit of 10KD, and then the filtrate was transferred to a new blue-capped bottle to further remove unwanted impurities. The blue-capped bottle was heated to 80 ℃ and stored overnight (10-18 hours), after which the filtrate (fifth extract) was cooled to room temperature. The obtained filtrate (fifth extract) was used in the subsequent experiment.

(H) The UV absorption value of the filtrate (fifth extract) obtained in (G) was measured, and then the absorbance at 270nm was adjusted to 0.4 to 0.5 by adding water for injection. In this case, the concentration of the effective component of the rabbit fur extract is about 1.2 NU/ml. The pH was then adjusted to 7.0. + -. 0.5 with 5 mol/LHCl.

(I) Sampling and detecting the product obtained in (H), wherein the sampling and detecting comprise the following steps: (1) HPLC detection was performed to confirm the content of 5 types of nucleic acid bases; (2) determining a characteristic of its LV absorption spectrum; (3) measuring the content of various amino acids; and (4) performing LC-MS/MS detection.

(J) And (D) carrying out moist heat sterilization on the product obtained in the step (H) at 121 ℃ for 20-30 minutes by using an autoclave, and storing for later use.

(1) HPLC detection

HPLC detection of the product obtained in (H) was performed using a high performance liquid chromatography system (Thermofeiser Scientific, Ul timeate 3000) according to the manufacturer's instructions using the following conditions:

sample introduction amount: 10 mu g of the solution; wavelength: 260.0 nm; flow rate: 0.6 ml/min; operating time: 20 min; dilution factor: 1.0.

the results of HPLC measurements are shown in Table 1 and FIG. 1.

TABLE 1 HPLC test results of rabbit skin extract from vaccinia virus-immunized rabbits

The HPLC assay results of table 1 and fig. 1 show that the prepared rabbit fur extract contains 5 types of nucleobases according to the relevant standards.

(2) Detection of LV absorption spectra

The product obtained in (H) was subjected to LV absorption spectroscopy using an ultraviolet spectrophotometer (Shimadzu, UV1800) according to the manufacturer's instructions. The results of detection of LV absorption spectra are shown in table 2 and fig. 2.

TABLE 2 detection of LV absorption spectra of rabbit skin extracts from vaccinia virus-immunized rabbits

Numbering	Wavelength (nm)	Absorbance of the solution
			1	339.60	0.062
2	269.80	0.484
			3	245.50	0.393

The HPLC test results in Table 2 and FIG. 2 show that the maximum absorbance of the prepared rabbit skin extract is in the range of 268-272 nm.

(3) Detection of amino acid content

The amino acid content of the product obtained in (H) was determined by ion chromatography (Dionex, ICS-3000) according to the manufacturer's instructions. The results of the amino acid content measurement are shown in Table 3.

TABLE 3 detection of amino acid content in rabbit skin extract from vaccinia virus-immunized rabbits

Species of	Content (mg/kg)
		Arginine	39.043
Lysine	0.375
		Alanine	7.393
Threonine	3.646
		Glycine	4.527
Valine	2.370
		Serine	7.586
Proline	3.472
		Isoleucine	11.723
Leucine	22.798
		Methionine	3.293
Histidine	1.323
		Phenylalanine	9.979
Glutamic acid	1.568
		Aspartic acid	1.950
Cystine	0.314
		Tyrosine ofAcid(s)	3.728

The results of the tests in Table 3 show that the prepared rabbit skin extract contains at least 13 amino acids.

(4) LC-MS/MS detection

In addition, the product obtained in (H) was also detected by LC-MS/MS method. Before the detection, the concentration (titer) of the rabbit skin extract obtained in (H) was adjusted to 1.2NU/ml, and a commercially available NTP injection (neurilepin/NEUR 0TR0PIN, 1.2NU/ml) was used as a control. The instruments used and the detection conditions were as follows:

liquid Chromatography (LC)

The instrument comprises the following steps: SHIMAZDU 20 AXR;

a chromatographic column: phennomonex Bi-phenyl 2.6um,3.0X 50 mm;

mobile phase A: water (containing 0.1% formic acid); mobile phase B: acetonitrile (containing 0.1% formic acid);

flow rate: 0.5 mL/min; sample introduction volume: 3 uL; column temperature: 35 ℃;

elution procedure:

second-order mass spectrum (MS/MS)

The instrument comprises the following steps: QTRAP5500(AB SCIEX), ESI source

MS/MS conditions:

parameters of ion source	Numerical value
		CUR	30psi
IS	5500(+),-4500(-)
		TEM	500℃
GS1	50psi
		GS
2	50psi

Compound detection conditions:

the quantitative results were as follows:

analyte	Prepared rabbit skin extract, ng/mL	NTP injection, ng/mL
			Citrulline	204	39.5
Carnosine	31.1	2.54
			GABA	179	0.463
L-carnitine	111	126

The above results show that the rabbit skin extract prepared in this example contains about 170ng citrulline, about 25.9ng carnosine and about 149ng GABA per NU unit, which is much higher than that of the commercial NTP injection; wherein, the content of GABA is increased by about 380 times, the content of carnosine is increased by about 12 times, and the content of citrulline is increased by about 5 times.

Example 2 evaluation of the Effect of Rabbit skin extract on promoting oligodendrocyte proliferation

This example uses oligodendrocytes to study the effect of the rabbit skin extract prepared in example 1 on its proliferation.

Oligodendrocytes were extracted from the cerebral cortex of SD female rats within 48h of neogenesis. After 5 passages, oligodendrocyte morphology was observed under microscope. Subsequently, cells after passage 5 were plated in polylysine-coated well plates. On day 1 after plating, the cultured cells were identified and characterized using oligodendrocyte-specific antibodies (anti-O4 antibody) and DAPI staining.

The results of the experiment are shown in FIGS. 3A-3C. FIG. 3A shows the results of immunofluorescence assay (fluorescence micrograph) of cultured cells with anti-O4 antibody. The results showed that the cultured cells were positive for the anti-O4 antibody detection and were oligodendrocytes. Fig. 3B shows the results of detection of cultured cells by DAPI staining (fluorescence micrograph), in which stained nuclei are shown. Fig. 3C is a merged image of fig. 3A and 3B. The results showed a 1:1 ratio of cells positive for anti-O4 antibody detection to cells stained with DAPI. This indicates that the cultured cells were oligodendrocytes and the cell purity was 100%.

Oligodendrocytes were plated at a density of 5000 cells per well in 96-well plates, setting 7 experimental groups and 1 control group, wherein:

the cell culture medium used in 7 experimental groups was DMEM/F12 medium, to which the concentrated rabbit skin extract prepared in example 1 was added so that the final concentrations in the culture medium were 0.2NU/ml, 0.5NU/ml, 1NU/ml, 1.5NU/ml, 2NU/ml, 2.5NU/ml, and 3NU/ml, respectively;

the cell culture medium used in 1 control group was DMEM/F12 medium supplemented with PBS.

The 8 groups of cells were incubated at 37 ℃ with 5% CO₂Culturing in an incubator. On

days

2, 4, and 6 after the start of culture, cells cultured in 96-well plates were subjected to proliferation assay using cck-8 kit at 450nm according to the kit instructions.

The results of the experiment are shown in FIGS. 4A-4C. FIGS. 4A-4C show the proliferation (absorbance measured at 450nm using cck-8 kit) of groups of oligodendrocytes cultured in cell culture media containing varying concentrations of rabbit skin extract at days 2 (FIG. 4A), 4 (FIG. 4B), and 6 (FIG. 4C), respectively, after the start of culture. The results show that the prepared rabbit skin extract has concentration and time dependence on the proliferation promoting effect of the oligodendrocyte. In addition, the results also show that the prepared rabbit skin extract can promote oligodendrocyte proliferation at a concentration of, for example, 0.5-3NU/ml in the cell culture medium. These results indicate that the prepared rabbit skin extract can promote the proliferation of oligodendrocyte. For example, oligodendrocytes may be cultured in a cell culture medium comprising an extract of rabbit skin at a concentration of 1.5NU/ml to promote proliferation of the cells.

Example 3 evaluation of the Effect of Rabbit skin extract on promoting proliferation of mesenchymal Stem cells

In this example, the rat femoral bone marrow mesenchymal stem cells were used to study the proliferation promoting effect of the rabbit skin extract prepared in example 1.

Bone marrow mesenchymal stem cells were extracted from the femurs of wistar female rats within 48h of newborn. After passage 5, bone marrow mesenchymal stem cells were plated in 96-well plates at a density of 5000 cells per well, and 7 experimental groups and 1 control group were set, in which:

the cell culture medium used in 7 experimental groups was DMEM/F12 medium, to which the concentrated rabbit skin extract prepared in example 1 was added so that the final concentrations in the medium were 0.2NU/ml, 0.5NU/ml, 1NU/ml, 1.5NU/ml, 2NU/ml, 2.5NU/ml and 3NU/ml, respectively;

days

2 and 4 after the start of culture, cells cultured in 96-well plates were subjected to proliferation assay using cck-8 kit at 450nm according to the kit instructions.

The results of the experiment are shown in FIGS. 5A-5B. FIGS. 5A-5B show the proliferation (absorbance measured at 450nm using cck-8 kit) of each group of mesenchymal stem cells cultured in cell culture medium containing rabbit skin extract at different concentrations on days 2 (FIG. 5A) and 4 (FIG. 5B) after the start of culture, respectively. The results show that the prepared rabbit fur extract has concentration and time dependence on the proliferation promoting effect of the bone marrow mesenchymal stem cells. In addition, the results also show that the prepared rabbit skin extract can promote the proliferation of the bone marrow mesenchymal stem cells at a concentration of, for example, 0.2-3NU/ml in the cell culture medium. These results indicate that the prepared rabbit skin extract can promote the proliferation of bone marrow mesenchymal stem cells. For example, mesenchymal stem cells may be cultured using a cell culture medium comprising an extract of rabbit skin at a concentration of 2NU/ml to promote proliferation of the cells.

Example 4 evaluation of the Effect of Rabbit skin extract in promoting proliferation of neural Stem cells

In this example, the effect of the rabbit fur extract prepared in example 1 on the proliferation promotion thereof was investigated using neural stem cells.

Extracting neural stem cells from cerebral cortex of SD rat fetal rat pregnant for 14 days in 5% CO₂DMEM/F12 cell culture medium (supplemented with bFGF, EGF, LIF and B27) was cultured. After 3 passages, the morphology of the cells was observed under a microscope. Subsequently, cells after passage 3 were plated in polylysine-coated well plates. On day 1 after plating, cultured cells were identified and characterized using neural stem cell-specific antibodies (anti-Nestin antibodies) and DAPI staining.

The results of the experiment are shown in FIGS. 6A-6D. Fig. 6A shows an optical micrograph of the cultured cells. The results showed that the cultured cells exhibited a shape of a cell sphere in suspension, which is transparent and has a strong stereoscopic impression and a radial burr on the periphery, and is unique to neural stem cells. FIG. 6B shows the results of immunofluorescence assay (fluorescence micrograph) of cultured cells with anti-Nestin antibody. The results showed that the cultured cells were positive for the detection of anti-Nestin antibody, and were neural stem cells. Fig. 6C shows the results of detection of cultured cells by DAPI staining (fluorescence micrograph), in which stained nuclei are shown. Fig. 6D is a merged image of fig. 6B and 6C. The results showed that the ratio of cells positive for anti-Nest in antibody detection to cells stained with DAPI was 1: 1. This indicates that the cultured cells were neural stem cells and the cell purity was 100%.

Neural stem cells were plated in 96-well plates at a density of 20000 cells per well, and 3 experimental groups and 1 control group were set, in which:

the cell culture medium used in 3 experimental groups was DMEM/F12 medium (supplemented with bFGF, EGF, LIF and B27), to which concentrated rabbit skin extract prepared in example 1 was added so that the final concentrations in the medium were 0.5NU/ml, 1NU/ml and 2NU/ml, respectively;

the cell culture medium used in 1 control group was DMEM/F12 medium (supplemented with bFGF, EGF, LIF and B27) supplemented with PBS.

The 4 groups of cells were incubated at 37 ℃ with 5% CO₂Culturing in an incubator. On

days

1, 2, and 3 after the start of the culture, cc was used according to the kit instructionsThe k-8 kit performs proliferation detection on cells cultured in a 96-well plate under the condition of 450 nm.

The results of the experiment are shown in FIGS. 7A-7C. Fig. 7A to 7C show the proliferation (relative cell survival) of each group of neural stem cells cultured in the cell culture medium containing the rabbit skin extract at different concentrations on days 1 (fig. 7A), 2 (fig. 7B), and 3 (fig. 7C) after the start of the culture, respectively. The results show that the prepared rabbit fur extract has concentration and time dependence on the proliferation promoting effect of the neural stem cells. In addition, the results also show that the prepared rabbit skin extract can promote the proliferation of the neural stem cells at a concentration of, for example, 0.5-2NU/ml in the cell culture medium. These results indicate that the prepared rabbit fur extract can promote the proliferation of neural stem cells. For example, neural stem cells may be cultured using a cell culture medium comprising an extract of rabbit skin at a concentration of 2NU/ml, thereby promoting proliferation of the cells. In addition, the results also show that the cultured neural stem cells still show suspended, transparent and strong stereoscopic impression and suspended cell ball shape with radial burrs around the periphery in the presence of the rabbit skin extract of 2NU/ml, and maintain the characteristics of the neural stem cells.

Example 5 evaluation of the Effect of Rabbit skin extract on neuronal cells of SD rat

In this example, the effect of the rabbit fur extract prepared in example 1 on primary neuronal cells of SD rats, in particular on the GABA signaling pathway (GABA receptor) of said cells, was evaluated using the patch clamp technique. The instrument used was the EPC10 amplifier system (HEKA corporation); the samples tested were rabbit skin extract (1.2NU/ml) prepared in example 1, and a commercially available NTP injection (1.2 NU/ml).

1. Materials and methods

1.1 reagents for the experiment

PBS/HEPES/Glucose buffer 6g Glucose, 7.38g HEPES, adding PBS 1000ml (TaKaRa, T900), using NaOH to adjust pH 7.38. And (5) filtering and sterilizing.

Cell adherence medium: 50ml of FBS (Gibco,10099-141), 0.55ml of glutamic acid (sigma, G1251-100G), 5ml of penicillin/streptomycin 100X (Hyclone, sv30010) were added to 500ml of DMEM medium (Gibco, 10313021).

Neurobasal medium: 10ML of B27Supplement (gibco,17504044), 1.25ML of L-glutamine 200mM (sigma,59202C-100ML),5ML of penicillin/streptomycin 100X (Hyclone, sv30010) were added to 500ML of Neurobasal Medium (gibco, 21103049).

1.2 Instrument for experiments

1.3 isolation and culture of rat hippocampal nerve cells

1) Treating the culture plate with polylysine to cover the bottom of the culture plate, sucking excess polylysine 30min later, and placing at 37 deg.C CO₂The incubator was overnight.

2) The culture plate was washed with PBS 2-3 times before the experiment and dried for future use.

3) PBS (containing sugar) was dispensed into 6 tubes each of 50ml and 15ml centrifuge tubes and frozen at-20 ℃ for 30min to make an ice-water mixture.

4) The experimental surgical instrument is divided into two parts and is put into isopropanol to be soaked for 1 h. One part of the method comprises the following steps: two fine tweezers, one iris scissors, one curved scissors and 1 ophthalmic scissors respectively, and one medicine spoon for stripping brain tissues; the other part is as follows: the pair of nerve forceps 2, the pair of scissors 1 and the pair of ophthalmic scissors are used for stripping the embryonic mouse.

5) Taking two boxes of crushed ice (an ice bag is arranged under the ice box), cleaning the experiment table, placing the ice bag on an experiment plate, and spraying alcohol to achieve sterility as much as possible.

6) 3-4 sterile 35mm dishes (built-in filters), 1ml pipette tips and sterile pipette tips were prepared.

7) Newborn SD rat suckling mice were sterilized with 75% ethanol and were rapidly decapitated.

8) The peeled brain was placed in ice PBS and allowed to stand for 2 min.

9) The brain was removed and placed in a dish containing ice PBS and a piece of filter paper was placed at the bottom to facilitate fixation of the brain tissue so that it did not slide in the dish.

10) The skull is stripped, the cerebral cortex is exposed and turned over, the thalamus is found, and the membrane on the surface is cleaned.

11) The thalamus was removed and placed in 10ml ice-containing PBS centrifuge tubes.

12) Free thalamus was washed 1-2 times in ice PBS.

13) PBS was blotted dry, typsin was added, and incubated in a 37 ℃ incubator for 20min, shaking every 5 min.

14) The enzyme-digested tissue was removed, the enzyme solution was aspirated, the reaction was stopped by adding ice-cold PBS, and the tissue was washed 2-3 times with PBS (without shaking the tissue).

15) Standing for 2min, and removing the upper liquid.

16) Adding 1ml of DMEM (for neuro) for whipping; blowing for 15 times, standing for 2min, collecting supernatant, and placing into a centrifuge tube (keeping the centrifuge tube at low temperature).

17) 1ml of DMEM was added, the pipetting was continued for 10 times, and the supernatant was collected and placed in the same dish. The procedure was repeated for a third additional 1ml, and after 3 times, the undigested tissue was discarded.

18) The collected supernatant was put into pre-plated plates (700000/well) (6 well plates) and shaken well.

19) After 4 hours, the dead cells and debris were aspirated off with gentle shaking, washed once with DMEM, and cultured in Neurobasal medium.

20) The next day, the medium was changed to Neurobasal medium by half. Thereafter, the change was made every other two days.

21) Establishing an epileptiform discharge model of hippocampal neurons: hippocampal neurons were plated out in vitro up to day 12. The magnesium-free treatment group was gently washed 3 times with magnesium-free HBSS to remove residual magnesium ions in the medium, and then cultured for 3 hours with magnesium-free HBSS, followed by recovery of normal medium or medium containing 10 μ M SSA, and detection was started after incubating the cells for 24 hours.

2. Electrophysiological recording

Acquisition of cellular electrophysiological signals was performed using EPC-10 amplifiers (HEKA) according to the manufacturer's instructions and the data was stored in PatchMaster (HEKA) software.

Briefly, a capillary glass tube (BF150-86-10, Sut ter instruments) was drawn into a recording electrode using a microelectrode drawing apparatus (P97, Sutter instruments). Filling of the electrode with internal liquid: 130mM CsCl,1.6mM MgCl₂10mM HEPES,5mM EGTA,2mM Na-ATP, pH 7.3. The recording electrode was brought into contact with the cells under an inverted microscope (IX71, Olympus) using a microelectrode manipulator (MP285, suter instruments) and a negative pressure was applied to the cells to form a G.OMEGA.seal. After G omega sealing is formed, rapid capacitance compensation is carried out, then negative pressure is continuously applied to the G omega sealing, cell membranes are broken through in a suction mode, and a whole cell recording mode is formed. Then, the compensation of the slow capacitor is carried out and the film capacitance and the series resistance are recorded.

GABA current recording method:

intracellular fluid: 130mM CsCl,0.1mM CaCl₂,2mM MgCl₂,1.1mM EGTA,5mM Na₂ATP and 10mM HEPES, pH 7.15, adjusted with CsOH;

extracellular fluid: 140mM NaCl,5mM CsCl,2mM CaCl₂,1mM MgCl₂5mM HEPES and 10mM Glucose, pH 7.35, adjusted with NaOH.

To the external liquid, 20. mu.M-DNQX, 20. mu.M-DAP 5 and 300nM-TTX were added.

Five minutes after stabilization at-70 mV in voltage clamp mode, recordings were made at-70 mV.

3. Results of the experiment

Using the above protocol, GABA currents of rat hippocampal neurons were recorded in the presence of GABA (10. mu.M), NTP injection + bicuculline (10. mu.M), rabbit skin extract prepared in example 1, or rabbit skin extract + bicuculline (10. mu.M) prepared in example 1 (experiments were performed with 2 cell samples, respectively). The concentration (titer) of NTP injection and rabbit skin extract is 1.2 x 10^-2NU/ml. Bicuculline is a competitive GABAA receptor antagonist and is used to specifically inhibit GABA signaling (current flow). The results of the experiments are shown in tables 4-5 and FIGS. 8A-8D.

Table 4: rat hippocampal neuronal cells responded to GABA current (pA) of rabbit skin extract prepared in example 1

Table 5: GABA current (pA) of rat hippocampal neuron cell response NTP

FIGS. 8A-8B show the GABA current response of cell sample 1 (FIG. 8A) and cell sample 2 (FIG. 8B), respectively, to GABA, rabbit skin extract of the invention or rabbit skin extract of the invention + dicentrine. FIGS. 8C-8D show the GABA current response to GABA, NTP injection or NTP injection + bicuculline for cell sample 1 (FIG. 8C) and cell sample 2 (FIG. 8D), respectively. The results show that the rabbit skin extract of the present invention can stimulate rat hippocampal neuronal cells to generate significantly stronger GABA current compared to NTP injection. This experimental result is consistent with the experimental conclusion (i.e., higher GABA content in the rabbit skin extract of the present invention) verified in example 1. The rabbit fur extract has better application prospect.

Example 6 evaluation of the therapeutic Effect of Rabbit skin extract on spinal cord injury

In this example, the therapeutic effect of the rabbit skin extract prepared as above on spinal cord injury was studied using a spinal cord injury model in rats.

Briefly, an animal Model of spinal cord injury was constructed using 8 week old female Wista rats, with spinal cord injury at 10 levels of the rat breast, using standard spinal cord injury percussion (impact Model II) at NYU. The rabbit skin extract prepared in example 1 was administered by intraperitoneal injection at a dose of 25NU/kg, 50NU/kg, 100NU/kg, respectively, 24 hours after injury, once a day, for 2 weeks after injury. In this experiment, it was shown that,meanwhile, 2 groups of negative controls were set, one group was rats without spinal cord injury, and the other group was spinal cord-injured rats treated with physiological saline. Subsequently, functional recovery and glial scar size of treated experimental animals were observed by BBB score (basal Beat tie Bresnahan motor function score) and gfap (global fibrous systemic acidic protein) immunostaining, according to basal DM, Beattie MS, Bresnahan jc.a. sensitive and reliable local adhesive rating scale for open field testing in rates.j neurotrautrauma 1995; 1-21, and according to the method described in Levi G.et al (acquisition of differential, and step as rocks in cerebellar greater than interchannel tissue) as viewed by student by GFAP immune lung and audiographic update pads with³H]D-aspartate and[³H]Brain res.1983nov; 312(2):227-41) to carry out GFAP immunostaining. The results of the experiments are shown in FIGS. 9-10.

FIGS. 9-10 show the effect of rabbit skin extract compared to normal saline on the treatment of spinal cord injured rats. Among them, fig. 9 shows motor function recovery (i.e., BBB score) after spinal cord injured rats were treated with physiological saline or a prescribed dose of rabbit skin extract. FIG. 10 shows glial scarring (i.e., GFAP immunostaining) in spinal cord injured rats treated with saline or a prescribed dose of rabbit skin extract.

As can be seen from fig. 9, the BBB score of the rat in the rabbit skin extract treatment group is significantly higher than that of the normal saline control group, which indicates that the rabbit skin extract of the present invention can significantly promote motor function recovery after spinal cord injury of the rat, and can be used for treating spinal cord injury. As can be seen from fig. 10, the expression level of GFAP of rats in the rabbit fur extract treatment group was significantly lower than that of rats in the control group, which indicates that the rabbit fur extract of the present invention can inhibit the formation of colloid scar and promote tissue repair and functional recovery after spinal cord injury.

The experimental results show that compared with a control group, the rabbit fur extract disclosed by the invention can obviously reduce the formation of colloid scars and promote the motor function recovery of rats after spinal cord injury. Therefore, the rabbit fur extract has determined curative effect on inhibiting spinal cord injury and inhibiting colloid scar formation.

While specific embodiments of the invention have been described in detail, those skilled in the art will understand that: various modifications and changes in detail can be made in light of the overall teachings of the disclosure, and such changes are intended to be within the scope of the present invention. The full scope of the invention is given by the appended claims and any equivalents thereof.

Claims

1. A process for preparing a rabbit skin extract, the process comprising the steps of:

(A) providing a pox-primed skin from a vaccinia virus-inoculated rabbit;

(B) mixing the skin with water and stirring for 2-10 hours to obtain a mixture;

subsequently, the pH of the mixture is adjusted to 9.5-10.5 and stirring is continued for 10-20 hours;

(C) performing solid-liquid separation on the product of step (B) to obtain a first extract; and

(D) preparing the rabbit fur extract by using the first extracting solution;

the step (D) includes the steps of:

(D1) adjusting the pH of the first extract to 4.0-5.0, performing heat treatment, and subsequently performing solid-liquid separation to obtain a second extract;

(D2) adjusting the pH of the second extract to 9.0-10.0, performing heat treatment, and performing solid-liquid separation to obtain a third extract;

(D4) performing solid-liquid separation on the product of the step (D3), and collecting the adsorbent; and

2. The method of claim 1, having one or more of the following features:

(1) the vaccinia virus is selected from the group consisting of a Lister strain of vaccinia virus, a Dalian (Dairen) strain of vaccinia virus, a Pond (Ikeda) strain of vaccinia virus, an EM-63 strain of vaccinia virus, a New York City public Health Board of Health strain of vaccinia virus, an Ankara (Ankara) strain of vaccinia virus, a Copenhagen (Copenhagen) strain of vaccinia virus, a Tiantan (Tiana Tan) strain of vaccinia virus, a WR strain of vaccinia virus, and a buffalo pox virus;

(2) the rabbit is selected from a hole rabbit, a hare, a rat rabbit and a snow rabbit;

(3) pre-treating the skin prior to performing step (B);

(4) in the step (B), the weight-to-volume ratio (g/ml) of the skin to the water is 1 (1-5);

(5) mixing the skin with water at room temperature and stirring for 2-10 hours in step (B), thereby obtaining a mixture;

(6) in step (B), adjusting the pH of the mixture to 9.5-10.5 using a base;

(7) in step (B), the pH of the mixture is adjusted to 9.5-10.5 and stirring is continued at elevated temperature for 10-20 hours;

(8) in the step (C), carrying out solid-liquid separation on the product of the step (B) by filtration or suction filtration;

(9) in step (B), no phenol is used;

(10) and (C) performing solid-liquid separation in the step (C), the step (D1), the step (D2) and the step (D4) by suction filtration, filtration and/or centrifugation.

3. The process of claim 1, wherein in step (B), no organic solvent is used.

4. The process of claim 1, which does not use phenol.

5. The process of claim 1, which does not use an organic solvent.

6. The method of claim 2, having one or more of the following features:

(1) the rabbit is selected from Japanese white breeding rabbit and New Zealand white breeding rabbit;

(2) the hare is a Japanese hare;

(3) the pretreatment comprises the following steps: freezing, thawing, washing, sterilizing, sonicating, fragmenting, or any combination thereof;

(4) in the characteristic (4), the weight-volume ratio (g/ml) of the skin to the water is 1 (1-1.5), 1 (1.5-2), 1 (2-2.5), 1 (2.5-3), 1 (3-4) or 1 (4-5);

(5) the room temperature is 15-20 ℃, 20-25 ℃, 25-30 ℃ or 30-35 ℃;

(6) in the feature (5), stirring is carried out for 2 to 4 hours, 4 to 6 hours, 6 to 8 hours or 8 to 10 hours;

(7) in the feature (6), the pH of the mixture is adjusted to pH10 using a base;

(8) in the feature (6), the base is an inorganic base;

(9) in the feature (7), the elevated temperature is 40 to 42 ℃, 42 to 45 ℃, 45 to 48 ℃ or 48 to 50 ℃;

(10) in the feature (7), the stirring is continued for 12 to 14 hours, 14 to 16 hours, 16 to 18 hours or 18 to 20 hours;

(11) in the feature (8), the product of the step (B) is filtered or suction-filtered with a filter pore size of 50 to 500. mu.m.

7. The method of claim 2, having one or more of the following features:

(1) the pretreatment comprises the following steps: prior to step (B), subjecting the skin to a disruption treatment, thereby disrupting the skin into particulate matter;

(2) in the feature (6), the base is NaOH or KOH;

(3) in the feature (8), the product in the step (B) is filtered or suction-filtered with a filtering pore size of 50-75 μm, 75-100 μm, 100-150 μm, 150-200 μm, 200-500 μm.

8. The method of claim 2, the pre-treatment being: before the step (B), the skin is subjected to a crushing treatment, so that the skin is crushed into particles, and the particle size of the particles is 50-75 μm, 75-100 μm, 100-150 μm, 150-200 μm or 200-500 μm.

9. The method of claim 1, having one or more of the following features:

(1) in the step (D1), adjusting the pH of the first extract to 4.0-5.0 using an acid;

(2) in step (D1), the pH of the first extract is adjusted to 4.0-5.0 and heated to 85-105 ℃;

(3) adjusting the pH of the second extract to 9.0-10.0 using a base in step (D2);

(4) in step (D2), the pH of the second extract is adjusted to 9.0-10.0 and heated to 85-105 ℃;

(5) in the step (D2), solid-liquid separation is performed by filtration or suction filtration to obtain a third extract liquid;

(6) in the step (D3), adjusting the pH of the third extract to 3.5-5.5 using an acid;

(7) in step (D3), the adsorbent is selected from the group consisting of activated carbon, kaolin, and any combination thereof;

(8) the weight ratio (g/g) of the adsorbent used in step (D3) to the skin used in step (B) is 1 (10-50);

(9) adjusting the pH of the third extract to 3.5-5.5 before, simultaneously with, or after the contacting with the adsorbent in step (D3);

(10) in the step (D3), the pH of the third extract is adjusted to 3.5 to 5.5 and contacted with an adsorbent, followed by stirring at room temperature for 1 to 4 hours;

(11) in the step (D3), the adsorbent is packed in an adsorption column, and then contacted with the pH-adjusted third extract liquid, thereby adsorbing the active substance in the third extract liquid;

(12) in the step (D4), the product of the step (D3) is subjected to solid-liquid separation by filtration or suction filtration to obtain an adsorbent having an active material adsorbed thereon;

(13) step (D5) comprises contacting the adsorbent with an extraction solvent having a pH of 9.0 to 11.0, followed by solid-liquid separation to obtain a fourth extract;

(14) in step (D5), the extraction solvent is a basic solution;

(15) the weight-to-volume ratio (g/ml) of the adsorbent used in the step (D3) to the extraction solvent used in the step (D5) is 1 (10-100);

(16) extracting the active material adsorbed on the adsorbent with the extraction solvent under heating and/or stirring in step (D5);

(17) extracting the active material adsorbed on the adsorbent with the extraction solvent one or more times in step (D5); the extracts obtained from each extraction are then combined to obtain a fourth extract.

10. The method of claim 1, having one or more of the following features:

(1) in step (D1), adjusting the pH of the first extract to 4.5 using an acid;

(2) in the step (D1), the pH of the first extract is adjusted to 4.0-5.0 and heated to 85-90 ℃, 90-95 ℃, 95-100 ℃ or 100-105 ℃;

(3) in the step (D1), the pH of the first extract is adjusted to 4.0 to 5.0, and the first extract is heated to 85 to 105 ℃, and the heating treatment is performed for 0.5 to 1 hour or 1 to 1.5 hours;

(4) in step (D2), adjusting the pH of the second extract to 9.5 using a base;

(5) in the step (D2), the pH of the second extract is adjusted to 9.0-10.0 and heated to 85-90 ℃, 90-95 ℃, 95-100 ℃ or 100-105 ℃;

(6) in the step (D2), solid-liquid separation is performed by filtration or suction filtration using a filter having a pore size of 0.22 to 0.65 μm, thereby obtaining a third extract;

(7) in step (D3), adjusting the pH of the third extract to 3.5-4.0, 4.0-4.5, 4.5-5.0, or 5.0-5.5 with an acid;

(8) the weight ratio (g/g) of the adsorbent used in the step (D3) to the skin used in the step (B) is 1 (10-15), 1 (15-20), 1 (20-25), 1 (25-30), 1 (30-40) or 1 (40-50);

(9) in the step (D3), the pH of the third extract is adjusted to 3.5 to 5.5, and is contacted with an adsorbent, followed by stirring at 15 to 20 ℃, 20 to 25 ℃, 25 to 30 ℃ or 30 to 35 ℃ for 1 to 4 hours;

(10) in the step (D4), the product of the step (D3) is subjected to solid-liquid separation by filtration or suction filtration using filter paper, thereby obtaining an adsorbent having an active substance adsorbed thereon;

(11) step (D5) comprises contacting the adsorbent with an extraction solvent having a pH of 9.0-11.0, followed by suction filtration, filtration and/or centrifugation to obtain a fourth extract;

(12) in step (D5), the extraction solvent is an alkaline aqueous solution, a methanol solution, an ethanol solution, an isopropanol solution, or any combination thereof;

(13) the weight-to-volume ratio (g/ml) of the adsorbent used in the step (D3) to the extraction solvent used in the step (D5) is 1 (10-20), 1 (20-30), 1 (30-40), 1 (40-50), 1 (50-60), 1 (60-70), 1 (70-80), 1 (80-90) or 1 (90-100);

(14) in the step (D5), the active substance adsorbed on the adsorbent is extracted at least 2 times with the extraction solvent, and then the extract solutions obtained in each extraction are combined to obtain a fourth extract solution.

11. The method of claim 1, having one or more of the following features:

(1) in the step (D1), the pH of the first extract is adjusted to 4.0-5.0 using a mineral acid;

(2) in the step (D2), the pH of the second extract is adjusted to 9.0-10.0 using an inorganic base;

(3) in the step (D2), the pH of the second extract is adjusted to 9.0 to 10.0, and the second extract is heated to 85 to 105 ℃, and the heating treatment is performed for 0.25 to 0.5 hour, 0.5 to 1 hour, or 1 to 1.5 hours;

(4) in the step (D2), after the second extract liquid is subjected to heat treatment, it is stirred for 10 to 12 hours, 12 to 14 hours, 14 to 16 hours, 16 to 18 hours or 18 to 20 hours, and then subjected to solid-liquid separation to obtain a third extract liquid;

(5) in the step (D2), solid-liquid separation is performed by filtration or suction filtration using a filter membrane having a pore size of 0.45 μm, thereby obtaining a third extract liquid;

(6) in step (D3), the pH of the third extract is adjusted to 3.5-5.5 and contacted with an adsorbent, followed by stirring at room temperature for 1-2 hours, 2-3 hours, or 3-4 hours;

(7) in the step (D5), the active material adsorbed on the adsorbent is extracted using an alkaline solution having a pH of 9.0 to 11.0;

(8) extracting the active material adsorbed on the adsorbent with the extraction solvent at a temperature of 40-42 ℃, 42-45 ℃, 45-48 ℃ or 48-50 ℃ and under stirring in step (D5);

(9) extracting the active material adsorbed on the adsorbent with the extraction solvent at a temperature of 40-50 ℃ for 1-2 hours, 2-3 hours, or 3-4 hours under stirring in step (D5);

(10) in the step (D5), the first extraction is performed with the extraction solvent having a pH of 9.0 to 10.0, and then the second extraction is performed with the extraction solvent having a pH of 10.0 to 11.0, and then the extracts obtained by the two extractions are combined, thereby obtaining a fourth extract.

12. The method of claim 1, having one or more of the following features:

(1) in step (D1), adjusting the pH of the first extract to 4.0-5.0 using HCl;

(2) in step (D2), adjusting the pH of the second extract to 9.0-10.0 using NaOH or KOH;

(3) in step (D3), adjusting the pH of the third extract to 3.5-5.5 using HCl;

(4) in step (D5), the extraction solvent is an alkaline solution having a pH of 9.0-9.5, 9.5-10.0, 10.0-10.5, or 10.5-11.0;

(5) in the step (D5), the active material adsorbed on the adsorbent is extracted with the extraction solvent under stirring, and the stirring is performed for 1 to 2 hours, 2 to 3 hours, or 3 to 4 hours.

13. The process of claim 1, wherein in step (D5), the extraction solvent is an aqueous solution of an inorganic base.

14. The process of claim 1, wherein in step (D5), the extraction solvent is an aqueous solution of NaOH or KOH.

15. The method of claim 1, wherein the method further comprises, after step (D), one or more steps selected from the group consisting of:

(E1) performing ultrafiltration on the fourth extract;

(E2) heating the fourth extract;

(E3) adjusting the pH of the fourth extract to 6.5-7.5;

(E4) diluting or concentrating the fourth extract;

(E5) sterilizing the fourth extract; and

16. The method of claim 15, having one or more of the following features:

(1) in step (E1), the molecular weight limit of ultrafiltration is 5-10KD, 10-15KD, 15-20KD, 20-30KD or 30-40 KD;

(2) in step (E2), the fourth extract is heated to 60-70 ℃, 70-80 ℃, 80-90 ℃ or 90-100 ℃, and optionally, left to stand for 10-12 hours, 12-14 hours, 14-16 hours or 16-18 hours;

(3) in step (E3), adjusting the pH of the fourth extract to 6.5-7.0 or 7.0-7.5 using an acid;

(4) in the step (E4), diluting the fourth extract with water for injection, physiological saline or physiological buffer;

(5) sterilizing the fourth extract in step (E5) using autoclaving, ultra high temperature sterilization (UHT), pasteurization, filter sterilization, or any combination thereof;

(6) the method comprises 1, 2, 3, 4, 5, or 6 of steps (E1) - (E6).

17. The method of claim 15, wherein in step (E3), the pH of the fourth extract is adjusted to 6.5-7.5 using a mineral acid.

18. The method of claim 15, wherein in step (E3), the pH of the fourth extract is adjusted to 6.5-7.5 using HCl.

19. A rabbit skin extract made by the method of any one of claims 1-18.

20. A rabbit skin extract free of any organic solvent and comprising at least 0.8ng of γ -aminobutyric acid per NU unit of rabbit skin extract, said rabbit skin extract being prepared by the method of any one of claims 1-18.

21. The rabbit skin extract of claim 20, having one or more of the following characteristics:

(1) the rabbit fur extract does not contain phenol;

(2) said rabbit skin extract further comprises at least 4ng carnosine per NU unit;

(3) the rabbit skin extract per NU unit also contains at least 60ng citrulline.

22. The rabbit skin extract of claim 20, having one or more of the following characteristics:

(1) the extract of rabbit skin contains 0.8-150ng gamma-aminobutyric acid per NU unit;

(2) 4-30ng carnosine is contained in the rabbit fur extract per NU unit;

(3) the extract of rabbit skin per NU unit also contains citrulline 60-200 ng.

23. The rabbit skin extract of claim 20, having one or more of the following characteristics:

(1) each NU unit of the rabbit skin extract contains 0.8-1ng, 1-2ng, 2-5ng, 5-10ng, 10-20ng, 20-50ng, 50-70ng, 70-100ng, 100-120ng or 120-150ng gamma-aminobutyric acid;

(2) each NU unit of rabbit skin extract contains 4-5ng, 5-7ng, 7-10ng, 10-12ng, 12-15ng, 15-20ng, 20-22ng, 22-25ng, or 25-30ng carnosine;

(3) each NU unit of rabbit skin extract contains 60-80ng, 80-100ng, 100-120ng, 120-150ng, 150-170ng, or 170-200ng citrulline.

24. A composition comprising rabbit skin extract of any one of claims 19-23.

25. The composition of claim 24, which is a cell culture medium or a pharmaceutical composition further comprising a pharmaceutically acceptable carrier or excipient.

26. The composition of claim 25, having one or more of the following characteristics:

(1) the cell culture medium is a DMEM culture medium, an F12 culture medium or a DMEM/F12 culture medium;

(2) the cell culture medium further comprises additional reagents;

(3) the pharmaceutical composition is an injection, a tablet or freeze-dried powder.

27. The composition of claim 26, wherein the additional agent is serum, a cytokine, a B27 cell culture additive, or any combination thereof.

28. The composition of claim 27, wherein the serum is fetal bovine serum; and/or

The cytokine is selected from the group consisting of Epidermal Growth Factor (EGF), Leukemia Inhibitory Factor (LIF), Fibroblast Growth Factor (FGF), or any combination thereof.

29. Use of an extract of rabbit skin according to any one of claims 19-23 for the manufacture of a medicament for spinal cord injury, for promoting motor function recovery after spinal cord injury, or for inhibiting glial scarring.

30. Use according to claim 29, which has one or more of the following characteristics:

(1) the glial scarring is that following a spinal cord injury;

(2) the spinal cord injury is spinal cord injury caused by spinal fracture or dislocation;

(3) the medicament further comprises a pharmaceutically acceptable carrier or excipient;

(4) the medicament is in a pharmaceutical dosage form suitable for systemic intravenous administration.

31. The use of claim 29, wherein the medicament is an injection or a lyophilized powder.